Newly identified insulin degradation enzyme inhibitor showed promising anti-diabetic effect


Posted August 5, 2014 by lorrainegenscript

Insulin degradation enzyme (IDE) knockout mice have elevated insulin levels, but exhibited impaired, rather than improved glucose homeostasis.

 
Insulin degradation enzyme (IDE) knockout mice have elevated insulin levels, but exhibited impaired, rather than improved glucose homeostasis. A recent Nature publication identified a physiologically active IDE inhibitor from a DNA-templated macrocycle library, allowing the study of IDE in a more specific manner than the knockout mice could. Treatment of both lean and obese mice with this inhibitor showed that IDE regulated not only insulin but also glucagon and amylin, demonstrating the feasibility of modulating IDE activity as a new strategy to treat type-2 diabetes. What are the underlying mechanisms?




In search of new therapeutic targets for type-2 diabetes, you may be challenged in getting your desired Ab. GenScript offers you the best solution, with its high quality custom monoclonal Ab, polyclonal Ab, and phospho-specific Ab to meet your specific research needs. With its world-class expertise and PhD-level technical support, GenScript will be a reliable partner for all your Ab production needs.
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By lorraine xu
Website Insulin degradation enzyme (IDE) knockout mice have elevated insulin levels, but exhibited impaired, rather than improved glucose homeostasis. A recent Nature publication identified a physiologically active IDE inhibitor from a DNA-templated macrocycle li
Country China
Categories Health
Tags antibody service
Last Updated August 5, 2014